Key takeaways
Eucrisa (crisaborole) and Dupixent (dupilumab) are both used to treat eczema, but they have some key differences. Eucrisa is a topical ointment that you apply to your skin, while Dupixent is an injectable medication. Eucrisa works by blocking the phosphodiesterase 4 (PDE4) enzyme to reduce inflammation and itching, and it's safe for children as young as 3 months. On the other hand, Dupixent is a monoclonal antibody that targets specific proteins to calm the immune system and is approved for children as young as 6 months. Both Dupixent and Eucrisa are only available as brand medications, but Dupixent is an injection, making it potentially more expensive. Additionally, Dupixent treats a wider range of conditions, including asthma and sinus congestion with nasal polyps, and is administered every other week or monthly, compared to Eucrisa's twice-daily application. Common side effects of Eucrisa include application site pain, while Dupixent can cause injection site reactions and eye inflammation.
